[Clinical aspects of a new, very low dose combination contraceptive]. / Klinische Aspekte eines neuen, sehr niedrig dosierten Kontrazeptivums vom Kombinationstyp.

In a multicentre trial in Yugoslavia 150 fertile women were treated during 2541 menstrual cycles with Ovoresta M, a new low-dosed combined oral contraceptive pill. Each tablet contains 0.75 mg lynestrenol and 0.0375 mg ethinyloestradiol. Evaluation of the results shows that there were no pregnancies. Irregular bleedings occurred in 8.1% of all cycles. The side effects recorded were mainly due to the fact that for 140 of the 150 participants this was the first oral contraceptive they ever used. 2 women dropped out for relevant reasons (irregular bleedings). Because of the low dosage of active ingredients the authors consider Ovoresta M a welcome supplement to the existing oral contraceptives.

PIP: Multicenter clinical trial of Ovoresta M, a low-dose combined oral contraceptive containing 0.75 mg lynestrenol and 0,0375 mg ethinyl estradiol, is reported. The trial included 150 women (2,541 treatment cycles). No pregnancies were observed in the group. Bleeding was seen in 95.1% of all treatment cycles between 2-6 days after the last pill was taken, and was not materially different from normal menstruation in 89.3% of cases. Irregular bleeding occurred in 8.1% of cycles. Other side effects included nausea and vomiting, headache, breast fullness, leg circulatory complaints, infections, nervousness, and depression; 140 patients had no previous treatment with oral contraceptives. 2 patients Dropouts included 3 patients who desired to become pregnant, 2 because of irregular bleeding, and 3 others for other reasons. Because of the low dosage of active ingredients the authors consider Ovoresta M a welcome supplement to existing oral contraceptives.

Critical dosages for oral contraceptives.

An investigation was carried out into the effectiveness of Ovostat E, a low dosage oral contraceptive. One hundred women, aged between 17 and 39 years, participated in the trial; 47 women completed 12 treatment cycles and 42 of these completed all 24 treatment cycles. The following results were obtained by computer analysis: Reliability was 100% and the Pearl Index therefore = 0; Cycle Control; length: an obvious regulating effect; 85-3% was the average percentage of women with a cycle length of 26 to 30 days; withdrawal bleeding occurred in 94-6% of cycles; duration of withdrawal bleeding: no change in 26-0%; 1--2 days shorter in 51-7%; 1--2 days longer in 5-6%; intensity of withdrawal bleeding: no change in 61-9%; decreased in 29-3%; increased in 3-4%; irregular bleedings occurred in 4-6% of cycles. The most common complaints were nervousness, headache and nausea, the last two virtually disappearing after the 3rd treatment cycle. Of the 49 women who continued the investigation for the further eighteen months, 2 dropped out because of intolerance, 1 because of objections to the periodic check-ups and 1 for reasons unknown.